

DESCRIPTION

Species Reactivity	Human/Mouse
Specificity	Detect human and mouse Tenascin C in Western blots.
Source	Monoclonal Rat IgG _{2A} Clone # 578
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse immature astrocyte-derived Tenascin C
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.


APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Immunocytochemistry	8-25 µg/mL	See Below
Neutralization	Husmann, K. <i>et al.</i> (1992) <i>J. Cell Biol.</i> 116 :1475.	
Western Blot	Morganti, M. <i>et al.</i> (1990) <i>Exp. Neurol.</i> 109 :98.	

DATA

Immunocytochemistry



Tenascin C in U-118 MG Human Cell Line.
Tenascin C was detected in immersion fixed U-118 MG human glioblastoma/astrocytoma cell line using Rat Anti-Human/Mouse Tenascin C Monoclonal Antibody (Catalog # MAB2138) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rat IgG Secondary Antibody (yellow; Catalog # NL013) and counterstained with DAPI (blue). View our protocol for [Fluorescent ICC Staining of Cells on Coverslips](#).

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Tenascin C, also known as hexabrachion, cytotactin, neuronectin, GMEM, J1, myotendinous antigen, glioma-associated-extracellular matrix antigen, and GP 150-225, is a member of the Tenascin family of extracellular matrix proteins. It is secreted as a disulfide-linked homohexamer whose subunits can vary in size from approximately 200 kDa to over 300 kDa due to differences in glycosylation (1). Rotary-shadowed electron micrographs of the purified molecule show six strands joined to one another at one end in a globular domain with each arm terminating in a knob-like structure (2, 3). The human Tenascin C monomer is synthesized as a precursor with a 22 amino acid (aa) signal sequence and a 2179 aa mature chain. The mature chain consists of a coiled-coil region (aa 118-145), followed by 15 EGF-like domains, 15 fibronectin type-III domains, and a fibrinogen C-terminal domain. In addition, there are 23 potential sites of N-linked glycosylation. Alternative splicing within the fibronectin type-III repeats produces six isoforms for human Tenascin C. Mature human Tenascin C (isoform 1) shares 84% aa sequence identity with mature mouse Tenascin C. In the developing embryo, Tenascin C is expressed during neural, skeletal, and vascular morphogenesis (1, 2). In the adult, it virtually disappears with continued basal expression detectable only in tendon-associated tissues (1, 2). However, great up-regulation in expression occurs in tissues undergoing remodeling processes seen during wound repair and neovascularization or in pathological states such as inflammation or tumorigenesis (1, 4, 5). Biologically, Tenascin C functions as an adhesion-modulatory extracellular matrix protein (1, 4-8). Specifically, it antagonizes the adhesive effects of fibronectin, and impacts the ability of fibroblasts to deposit and contract the matrix by affecting the morphology and signaling pathways of adherent cells (5-7). Tenascin C acts by blocking syndecan-4 binding at the edges of the wound and by suppressing fibronectin-mediated activation of RhoA and focal adhesion kinase (FAK) (4-8). Tenascin C thus promotes epidermal cell migration and proliferation during wound repair.

References:

1. Hsia, H.C. and J.E. Schwarzbauer (2005) *J. Biol. Chem.* **280**:26641.
2. Nies, D.E. *et al.* (1991) *J. Biol. Chem.* **266**:2818.
3. Erickson, H.P. and J.L. Iglesias (1984) *Nature* **311**:267.
4. Orend, G. *et al.* (2003) *Oncogene* **22**:3917.
5. Wenk, M.B. *et al.* (2000) *J. Cell Biol.* **150**:913.
6. Midwood, K.S. *et al.* (2004) *Mol. Biol. Cell* **15**:5670.
7. Midwood, K.S. and J. E. Schwarzbauer (2002) *Mol. Biol. Cell* **13**:3601.
8. Hsia, H.C. and J.E. Schwarzbauer (2006) *J. Surg. Res.* **136**:92.